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Abstract
There is a strong current trend for using complementary and alternative medications to treat atopic dermatitis. Atopic dermatitis
is a common, chronic, pruritic, and inflammatory skin disease. It can have a profound, negative effect on patients’ quality of life.
Mild cases of atopic dermatitis can be controlled by the application of moisturizers and topical corticosteroids. However, in
severe cases, application of immunosuppressive medication is unavoidable but it can have adverse effects. In traditional Persian
medicine, diseases similar to resistant atopic dermatitis are treated with whey in combination with decoction of field dodder. Both
whey and field dodder have anti-inflammatory properties. Consumption of whey can also aid skin repair, mitigate pruritus, and
help combat the high level of stress experienced by patients. Therefore, it is hypothesized that consumption of traditional
medicinal treatment of whey with decoction of field dodder can be applied as a complementary treatment for atopic dermatitis.
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Atopic dermatitis is a chronic and pruritic inflammatory skin
disease characterized by exacerbation and remission of symp-
toms. Pruritus is a characteristic feature of atopic dermatitis
that can be followed by disease flare-up and secondary infec-
tion through creating a vicious cycle of pruritus-scratching.
Pruritus can flare up both in affected areas of the skin and in
seemingly healthy regions.1,2
Atopic dermatitis has a relapsing and chronic pattern. Clinical
manifestations can be different, but diagnosis is usually based on
Hanifin and Rajka criteria.3 Atopic dermatitis usually emerges
during infancy or childhood, but it can continue through to adult-
hood or its onset may be in adulthood. Atopic dermatitis has dif-
ferent patterns according to different age of onset. In infants, it is
usually manifest as exudative erythematous papules and vesicles
with severe pruritus in the face and scalp. From the age of 2
years until puberty, the disease pattern varies and exudative
lesions are replaced by papules and chronic lichenified plaques
affecting mostly hands, feet, popliteal and ante cubital areas,
knees, and wrists. In adults, the most commonly affected areas
are hands, feet, fingers, toes, face, neck, flexural folds, arms, and
the back. Evidence has shown that before the emergence of ato-
pic dermatitis, there is atopy and the disease can be accompanied
by other atopic diseases such as asthma and allergic rhinitis.4-6
Less than half of children suffering from atopic dermatitis may
be in complete remission by the age of 7 years; however, at most
60% of patients recover by adulthood, demonstrating the chronic
nature of the disease.7
Atopic dermatitis is a chronic disease and as such it has a
profoundly unpleasant impact on quality of life among people
suffering from the condition.5,8 Pruritus and skin lesions dis-
rupt sleeping patterns and affect social performance of patients,
and unsightly skin lesions can cause patients to isolate them-
selves from other people.9,10
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Prevalence of atopic dermatitis has become 3-fold since
1960. Atopic dermatitis is a general public health problem and
affects more than 20% of children and 3% of adults.2,11 The
female-to-male ratio for incidence of the disease is 1/3 to 1.5
Research has shown that prevalence of atopic dermatitis is over
10% in developing countries. This figure is increasing, but it has
reached a constant level of about 20% in developed countries.12
In the United States, the annual cost of medication and medical
care spent controlling this disease amounts to approximately
US$1 to 4 billion. This value does not include significant indirect
costs related to loss of working hours for patients.13
Atopic Dermatitis and Complementary and
Alternative Medicine
Pathophysiology of Atopic Dermatitis
Skin dryness and pruritus are 2 characteristic features of atopic
dermatitis. Atopic dermatitis occurs in individuals who are
genetically predisposed. Genetic studies have noted the role of
epidermal differentiation complex in atopic dermatitis.14 In addi-
tion, mutations in the filaggrin gene, related to an important pro-
tein in the structure of epidermis, have also been observed.15,16
The amount of endogenic proteolytic enzymes in the skin
increases in people suffering from atopic dermatitis. The skin
faces decreased amounts of ceramides in both affected and unaf-
fected areas. Ceramides are the main water-preserving mole-
cules within the extracellular space in the cornified layer.17
These aforementioned skin conditions result in skin dryness that
then allows pathogens, antigens, and irritants to enter the body
through microscopic pores leading to inflammation and infec-
tion.18,19 Furthermore, dysregulation of the immune system
occurs particularly in 2 main subgroups of CD4þ cells, T-
helper 1 and T-helper 2.2 The number of blood eosinophils
increases. In the allergic or extrinsic type accounting for 70%
to 80% of the cases, patients have high levels of serum IgE.
However, in 20% to 30% of patients, there is no significant
increase in the level of IgE, and accordingly, it is termed as non-
allergic or intrinsic-type atopic dermatitis.19 The intrinsic type
can be a harbinger of extrinsic atopic dermatitis.20
In this disease, disorders in the immune system lead to prob-
lems related to skin barrier function. These problems themselves
bring about further problems that culminate in an abnormal
response to irritants, allergens, and microbial organisms.2,21
Treatment of Atopic Dermatitis in Modern Medicine
Atopic dermatitis has an exacerbating-remitting pattern that
varies from one patient to the next. In modern medicine, the
major objective is to reduce intensity and frequency of disease
flare-ups, for which different pharmacological and nonpharma-
cological methods are used.2 The first line of defense is to
detect irritant factors and avoid them.1 Preventive treatment
can reduce disease episodes through proper skin humidifica-
tion. This is managed by relieving itching and thereby disrupt-
ing the vicious cycle of pruritus-scratching.22,23 Application of
a humid bandage, immersion in a warm water bath for a short
period, application of hydrophilic ointment, and restora-
tive ceramide-rich covers are examples of appropriate
treatments.24-26
Topical corticosteroid medication is commonly applied to
treat atopic dermatitis, but can have side effects; hence, many
physicians prefer to prescribe such medication only in cases
of an acute attack.27,28 However, pharmacological studies have
shown that there is potential for systemic absorption, even in
weak topical corticosteroids.29,30
Calcineurin inhibitors are also effective by inhibiting T cells
and mast cells.31,32 Although tacrolimus ointment and pimecroli-
mus cream are both effective and particularly useful in individuals
unable to tolerate other topical treatments, they have numerous
complications and long-term safety has not yet been proven.33,34
Sedative antihistamines are used as an auxiliary medica-
tion mainly applied to relieve sleep disturbance caused by
pruritus.35,36
Severe and resistant cases of atopic dermatitis may require
systemic treatment such as administration of oral steroids,
cyclosporine, mycophenolate mofetil, azathioprine, methotrex-
ate, or interferon. Phototherapy can also provide therapeutic
response in such cases. However, numerous investigations
have been done to determine the effectiveness and identify
complications of these treatments, and results have shown that
they do not necessarily have suitable efficacy long term and can
have serious unwanted side effects.22,37-41
In summary, there is no definite treatment for atopic derma-
titis in modern medicinal practice, and disease control is based
on identification and avoidance of factors that stimulate a flare-
up, sufficient hydration of the skin, control of pruritus and
infection, and proper usage of topical corticosteroids in mild
cases. Severe and resistant cases are often treated with immu-
nosuppressive medication.1 Due to numerous adverse effects
associated with immunosuppressive drugs, safer therapeutic
treatment is required. Nowadays, there is a strong tendency
toward complementary therapeutic methods for treating atopic
dermatitis.42 Traditional Persian medicine is a complementary
medicine that presents an effective treatment. Among these
traditional Persian medicinal treatments is whey with the
decoction of field dodder, used to treat skin diseases with
symptoms similar to atopic dermatitis.43-46
Atopic Dermatitis From the Traditional Medicine
Perspective and Its Treatment
In traditional Persian medicine, Ghouba disease is cited as hav-
ing symptoms, types, and a clinical course very similar to ato-
pic dermatitis. Among different types of Ghouba, melancholic
Ghouba is very similar to chronic and resistant atopic dermati-
tis. In traditional medical texts, Ghouba has been defined as a
kind of roughness apparent in the skin, which accompanies
severe pruritus that is first manifest as small and slightly hard
papules that produce discharge after being scratched and that
then spread across the body. The margin of lesions is slightly
lumpy, where some circular thin scales like fish scales might
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become detached from a lesion. Ghouba can be accompanied
by discharge or have no discharge; it can cause burning sensa-
tion or have no burning sensation, desquamation of the skin or
not, and the condition may be progressive, acute, or chronic.
Ghouba has 3 types: bloody, phlegmatic, and melancholic.
Lesions are red, white to red or yellow, and dark in bloody,
phlegmatic, and melancholic types, respectively. Bloody and
phlegmatic type lesions improve faster than melancholic ones.
Scratching induces secretion in the bloody type. When lesions
are dry with no discharge, they are mostly melancholic. The
worst and most chronic form is melancholic; this type of lesion
is dark, lumpy, and rough.43-46
Ghouba has 3 stages: initially, the causative agent is only
subcutaneous, and the condition may heal easily. In the second
stage, the causative agent penetrates to deeper regions resulting
in delayed recovery. In the third stage, whereby the agent has
spread, it is problematic to heal and can become chronic, par-
ticularly when the agent is melancholic. Traditional medicine
attributes such conditions to consumption of certain types of
food such as fish, beef, banana, mango, and eggplant.43,45
In traditional medicine, blood donation, avoidance of its
developing factors, short but frequent warm-water baths, and
application of topical medicines after bathing can be useful
to treat Ghouba. In both secreting and dry lesions, topical dry-
ing agents and moisturizers can be used, respectively.43-46
In terms of symptoms, bloody and phlegmatic types of
Ghouba have great similarity to childhood- and adolescence-
onset of atopic dermatitis, but the melancholic type is more
similar to chronic and resistant atopic dermatitis. Traditional
medical texts mention that chronic and melancholic Ghouba
require identical treatment. One treatment that is emphasized
in traditional Persian medicine is that of whey with a decoction
of field dodder. In traditional medicine, application of whey
has been highly recommended for hydration of the body and
has been mentioned as the best medicine for melancholic dis-
eases. Whey is of particular significance in the treatment of this
disease because it has a high level of digestive absorption, lack
of any side effect, aids in excretion of melancholy and body
hydration, and provides fats that are essential to the body.
Decoction of field dodder used with whey is among medicinal
treatments commonly used to treat melancholic diseases.43-46
Whey
Whey is a by-product of cheese production. After adding rennet
(chymosin) or organic acids (lactic, acetic, or citric acids) or
mineral acids to milk, casein proteins are coagulated and sepa-
rated to form crud, and whey is the yellow-greenish liquid
remains of the process. This protein complex derived from milk
contains valuable constituents.47
Whey has antioxidant, antitumor, antiviral, antibacterial,
and antifungal properties and can reduce problems with blood
pressure and hyperlipidemia. The beneficial effect of whey
consumption for prevention and treatment of cardiovascular
diseases, cancer, HIV, hepatitis B, and osteoporosis has been
confirmed in clinical trials reported in various studies.48
Whey proteins contain essential amino acids in higher con-
centrations than plant proteins, so absorption is more effective
compared with free amino acid solutions.49,50 Whey is also rich
in sulfur-containing amino acids such as cysteine and methio-
nine that provide whey with antioxidant properties, because
cysteine changes into glutathione, a potent intracellular antiox-
idant. This antioxidant activity has made whey an anti-ageing
agent.50,51 It has a high concentration of branched amino
acids, valine, isoleucine, and in particular leucine. Leucine
is an essential amino acid involved in the process of protein
synthesis.52
Biological components of whey consist of b-lactoglobulin,
a-lactalbumin, lactoferrin, lactoperoxidase, bovine serum albu-
min, glycomacropeptide, and immunoglobulins that support
the immune system.48
Lactoferrin in whey is able to activate natural killer cells and
neutrophils.53-56 It has antiviral, antibacterial, antifungal, and
anti-inflammatory properties.57,58 a-Lactalbumin in whey can
diminish oxidative stress by chelating heavy metals.47,59
Although investigations have shown that the components of
whey have anti-inflammatory properties and help repair skin
structure, no studies have evaluated the efficacy of whey on
atopic dermatitis thus far.
Field Dodder
Field dodder, with the scientific name of Cuscuta campestris
Yuncker and the traditional name Aftimoun is used to treat epi-
lepsy, cancer, insanity, paralysis, and dermatological diseases
in traditional medicine.60 It is a parasitic plant belonging to
the family Convolvulaceae. This family includes species such
as Cuscuta campestris, C. epithymum, C. chinensis, and
C. reflexa. Field dodder has the highest diversity among various
Cuscuta species and can grow in various areas of the world.61
Field dodder is an annual parasitic plant. It has no leaves and
chlorophyll.62 This plant has anti-inflammatory, antiprolifera-
tive, and analgesic properties.63 Quercetin and kaempferol
flavonoids present in extract of field dodder seeds have
immune-modulating and anti-inflammatory properties.64 Based
on studies, consuming dodder at the conventional doses has no
complications, but its high dose may cause diarrhea or intestinal
colic.65 In modern phytotherapy, the average safe amount of
field dodder for daily use has been mentioned to be 2 grams.66
No research has been done to date on potential effects of field
dodder on atopic dermatitis.
Discussion and Conclusion
Important pathophysiological dimensions of atopic dermatitis
are dysregulation of the immune system and abnormal skin bar-
rier function as a result of genetic and environmental factors.
The water content of the cornified layer of the skin and super-
ficial lipids, where ceramides are the main constituents, play an
important role in skin appearance and function. Disruptions in
the balance between these 2 constituents contribute to dryness
of the skin.17,19
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In atopic dermatitis, there is an abnormality in cornified
envelope genes that contributes to reduce ceramide levels. Cer-
amides constitute a major part of cornified layer lipids and have
an important role in preserving water at the extracellular space
in this layer. The amount of endogenic proteolytic enzymes
increases and this disrupts the skin barrier function and thus
water loss through the skin is intensified. This induces skin dry-
ness, generating microscopic breaks and pores through which
pathogens, irritants, and allergens are easily absorbed into the
skin, which causes inflammation and infection.18
In atopic dermatitis, dysregulation of the immune system
exists particularly in 2 main subgroups of CD4þ T cells:
T-helper 1 and T-helper 2 cells. Analysis of biopsies in patients
suffering from atopic dermatitis indicates that T-helper 2
immune responses increase compared with responses in healthy
skin.67 In atopic dermatitis, treatment is comprehensive and
complete when we consider pathophysiological aspects of this
disease, dysregulation of the immune system, and disruptions
in skin barrier functioning, simultaneously. Administration of
whey with the decoction of field dodder has been widely used
in traditional Persian medicine to treat Ghouba disease, a dis-
order very similar to atopic dermatitis in terms of symptoms,
stages, and course of the disease.43-46 Possessing unique char-
acteristics, this medication may be effective in both improving
skin barrier function and modification of disruption of the
immune system (Table 1). Whey is a food supplement contain-
ing valuable components with important nutritional and biolo-
gical properties. No severe adverse effects or complications
have been reported for this substance so far. Whey is consid-
ered a highly nutritional material as it contains a wide range
of essential and nonessential amino acids, biologically active
proteins, minerals, and lipids.48 It has a high concentration of
branched amino acids particularly leucine, an important com-
ponent in the process of tissue regeneration and development.52
Therefore, it can aid improvement of skin lesions and modifi-
cation of skin barrier function.
The skin’s defense mechanism against various external
factors such as transient pathogens has components including
antimicrobial lipids such as sapienic acid and sphingosine and
antimicrobial peptides such as b-defensins and cathelicidin.68-
72 The extent of these antimicrobial components is lower in the
skin of patients suffering from atopic dermatitis compared with
levels in healthy individuals. This contributes to higher inci-
dence of secondary infection in skin lesions of atopic dermatitis
patients.68,69,73 Lactoferrin, b-lactoglobulin, lactoperoxidase,
lysozyme, anionic peptides, and some free fatty acids in whey
have antibacterial, antifungal, and antiviral properties.74-77
This explains the effect of whey in reducing secondary bacter-
ial and fungal infections of lesions in atopic dermatitis. Lac-
toferrin also has anti-inflammatory properties capable of
relieving symptoms of the disease through regulation of tumor
necrosis factor-a level elevated in atopic dermatitis, which
initiates or contributes to inflammation.58,78
Atopic dermatitis is a disease in which relapse often occurs,
and its chronic course and complications have a negative influ-
ence on the quality of life. Research has indicated that con-
sumption of whey can enhance serotonin levels in the brain,
thereby enabling patients suffering from atopic dermatitis to
cope with the high level of stress associated with the disease.79
Furthermore, serotonin has an immune-modulatory effect that
inhibits T cells and relieves pruritus, one of the most annoying
symptoms of atopic dermatitis.80
Whey contains Milk Basic Protein, which provides another
advantage in controlling atopic dermatitis. Milk Basic Protein
stimulates osteoblast proliferation and differentiation and is
able to reduce the risk of osteoporosis and osteopenia develop-
ment, usually caused by the inflammatory nature of the disease
and long-term consumption of corticosteroids.81,82 Studies
have demonstrated that even substitution of whey for standard
formula to feed infants with a positive familial history of atopic
dermatitis can reduce the chance of developing further out-
breaks of the disease.83
Table 1. The Probable Mechanism of Action of Whey With Field Dodder Extract in Atopic Dermatitis.
Components Mechanism of Action Efficacy in Atopic Dermatitis
Whey Branched amino acids particularly
leucine
Tissue regeneration and development Improvement of skin lesions
Modification of skin barrier function
Lactoferrin; b-lactoglobulin;
lactoperoxidase; lysozyme; anionic
peptides; some free fatty acids
Antibacterial, antifungal, and antiviral
properties
Reduction of secondary bacterial and
fungal infections of lesions
Lactoferrin Regulation of TNF-a level Decrease of inflammation
a-Lactalbumin Enhancement of serotonin level Improvement of stress coping
Inhibition of T cells and relief of pruritus
Milk Basic Protein Stimulation of osteoblast proliferation and
differentiation
Reduction of the risk of osteoporosis
and osteopenia development
Field dodder
extract
Quercetin and kaempferol Regulation of underlying inflammation factors
such as inducible nitric oxide synthase
and cyclooxygenase-2
Decrease of inflammation
Quercetin Inhibition of mast cell secretions Reduction of flare-ups
Inhibition of the production of T-helper 2
cytokines
Decrease of inflammation
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Seeds of field dodder contain quercetin, kaempferol flavo-
noids and have been used in traditional medicine as a decoc-
tion to treat melancholic disease; these flavonoids have
anti-inflammatory and antiproliferative properties.84 Querce-
tin blocks the intermediates involved in allergies and can act as
an inhibitor of mast cell secretion, a very important factor in the
pathogenesis of atopic dermatitis attacks.85 Quercetin and
kaempferol flavonoids exert anti-inflammatory features by
regulating underlying factors that cause inflammation such
as inducible nitric oxide synthase and cyclooxygenase-2.64
Nitric oxide derived from inducible nitric oxide synthase is
involved in atopic dermatitis flare-ups and in pathogenesis of
allergic rhinitis.86 In atopic dermatitis, cytokines produced by
T-helper 2 cells reduce the expression of skin barrier proteins.87
Quercetin abundant in decoction of field dodder is able to pres-
ent significant anti-inflammatory effects by inhibiting the pro-
duction of cytokines from T-helper cells.85 Recent research has
shown that when field dodder seeds are used in decocted form,
the heating process leads to significant elevation of quercetin
levels compared with unheated seeds, and this serves to rein-
force anti-inflammatory and antiproliferative properties of the
substance.88 Accordingly, it can be stated that field dodder can
be advantageous in improving atopic dermatitis lesions by acti-
vating an inflammation-reducing mechanism. Consumption of
therapeutic doses of field dodder has no adverse effects, but
overdose can cause intestinal colic and diarrhea.65
It is hypothesized that consumption of whey, together with
field dodder, can target important pathophysiological aspects
of atopic dermatitis by reducing inflammation, aiding immuno-
modulation, improvement of skin lesions, and modification of
skin barrier function. This combination can also be used as a
complementary treatment for atopic dermatitis, with the least
complications, for reducing intensity and frequency of attacks.
It is suggested that efficacy of this medication be investigated
by conducting clinical trials after preparation of standard
formulations.
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